Sung-Bae Kim, Professor at Asan Medical Center, Institute for Innovative Cancer Research, shared a post on X:
“Honored to speak at ESMOBreast26 today on ՛Adjuvant CDK4/6 inhibitors: Could they replace chemo for intermediate-risk ER+ eBC?՛ Outstanding educational session chaired by Sibylle Loibl with C. Denkert, FC. Bidard and H. Parsons.
Reflecting on my 3 years as Scientific Co-Chair (2021–2023) – proud and grateful to have helped bring more Asian voices to the ESMO Breast stage and foster global networking.
To everyone who’s been part of this journey – thank you. See you in Milan for ESMOBreast27.”
After CDK4/6 Inhibitors: How Oral SERDs Are Reshaping HR+/HER2− Metastatic Breast Cancer
